CFO
BIIB icon

Callan Family Office’s Biogen BIIB Stock Holding History

Callan Family Office’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Sell
6,183
-316
-5% -$60.4K 0.03% 517
2026
Q1 		$1.19M Sell
6,499
-2,496
-28% -$460K 0.03% 513
2025
Q4 		$1.58M Buy
8,995
+6,843
+318% +$1.12M 0.03% 412
2025
Q3 		$301K Sell
2,152
-302
-12% -$40.8K 0.01% 708
2025
Q2 		$308K Buy
+2,454
New +$306K 0.01% 761

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Callan Family Office's BIIB Position: Q2 2026 in Review

Callan Family Office reduced its Biogen (BIIB) stake by 4.9% in Q2 2026, selling an estimated $60.4K and leaving 6,183 shares worth $1.34M. The position accounts for 0.03% of the portfolio, ranked #517.

Callan Family Office first reported a position in BIIB in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.58M in Q4 2025. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Callan Family Office held 6,183 shares of Biogen worth $1.34M as of Q2 2026.
  • Callan Family Office sold 316 Biogen shares in Q2 2026, an estimated $60.4K.
  • Biogen made up 0.03% of Callan Family Office's portfolio in Q2 2026, its #517 holding.
  • Callan Family Office first reported a position in Biogen in Q2 2025 and has held it in 5 quarters since.
  • Callan Family Office's Biogen position peaked at $1.58M in Q4 2025.
  • 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.